BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC)
- First Posted Date
- 2012-03-23
- Last Posted Date
- 2022-08-24
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 109
- Registration Number
- NCT01562028
- Locations
- 🇫🇷
Centre Francois Baclesse, Caen, France
🇫🇷Hôpital de Marseille, Marseille, France
🇩🇪Hospital Grosshansdorf, Grosshansdorf, Germany
Study of Changes in Estrogen Levels and Grip Strength in Postmenopausal Women Who Have Received 4 to 6 Years of Hormone Therapy for Breast Cancer and Are Currently Receiving Letrozole on Clinical Trial IBCSG-35-07
- Conditions
- Breast Cancer
- First Posted Date
- 2011-01-21
- Last Posted Date
- 2021-10-06
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 104
- Registration Number
- NCT01281137
- Locations
- 🇦🇺
Box Hill Hospital, Box Hill, Victoria, Australia
🇧🇪CHU Liege - Domaine Universitaire du Sart Tilman, Liege, Belgium
Study of Estrogen Levels in Premenopausal Women Who Have Undergone Surgery for Breast Cancer and Are Receiving Triptorelin and Tamoxifen Citrate or Exemestane on Clinical Trial IBCSG 24-02
- Conditions
- Breast Cancer
- First Posted Date
- 2009-09-11
- Last Posted Date
- 2021-10-25
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 123
- Registration Number
- NCT00975676
- Locations
- 🇫🇷
Centre Rene Huguenin, Saint-Cloud, France
🇭🇺National Institute of Oncology, Budapest, Hungary
🇮🇹Salvatore Maugeri Foundation, Pavia, Italy
Study of Bone Mineral Density in Women With Breast Cancer Treated With Triptorelin and Tamoxifen or Exemestane on Protocol IBCSG 25-02
- Conditions
- OsteoporosisBreast Cancer
- First Posted Date
- 2009-08-21
- Last Posted Date
- 2023-05-31
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 119
- Registration Number
- NCT00963417
- Locations
- 🇦🇺
Royal Brisbane and Women's Hospital, Brisbane, Australia
🇦🇺Peter MacCallum Cancer Center, East Melbourne, Australia
🇦🇺Box Hill Hospital, Melbourne, Australia
Fingernails in Evaluating Bone Health in Postmenopausal Women With Breast Cancer Undergoing Hormone Therapy on Clinical Trial IBCSG-1-98
- Conditions
- Breast CancerOsteoporosis
- First Posted Date
- 2009-05-12
- Last Posted Date
- 2012-07-27
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 60
- Registration Number
- NCT00899288
Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG 24-02
- Conditions
- FatigueBreast CancerSleep Disorders
- Interventions
- First Posted Date
- 2008-04-16
- Last Posted Date
- 2016-07-25
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 86
- Registration Number
- NCT00659373
- Locations
- 🇺🇸
Mercy General Hospital, Sacramento, California, United States
🇺🇸Front Range Cancer Specialists, Fort Collins, Colorado, United States
🇺🇸Norwalk Hospital, Norwalk, Connecticut, United States
Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer
- First Posted Date
- 2007-11-04
- Last Posted Date
- 2020-03-11
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 4884
- Registration Number
- NCT00553410
- Locations
- 🇺🇸
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Faulkner Hospital, Boston, Massachusetts, United States
🇦🇺Armidale Hospital, Armidale, New South Wales, Australia
Bone Density and Bone Loss in Postmenopausal Women With Breast Cancer Receiving Treatment in Clinical Trial IBCSG-1-98
- Conditions
- Breast CancerOsteoporosis
- First Posted Date
- 2006-08-29
- Last Posted Date
- 2012-07-27
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 458
- Registration Number
- NCT00369850
- Locations
- 🇦🇺
Institute of Oncology at Prince of Wales Hospital, Randwick, New South Wales, Australia
🇦🇺Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia
🇫🇷Institut Bergonie, Bordeaux, France
Cognitive Function in Postmenopausal Women With Breast Cancer Receiving Hormone Therapy on Clinical Trial IBCSG-1-98
- Conditions
- Cognitive/Functional EffectsPsychosocial Effects of Cancer and Its TreatmentBreast CancerFatigue
- First Posted Date
- 2006-06-23
- Last Posted Date
- 2012-07-27
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 135
- Registration Number
- NCT00343616
- Locations
- 🇦🇺
Institute of Oncology at Prince of Wales Hospital, Randwick, New South Wales, Australia
🇦🇺Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
🇦🇺St. Vincent's Hospital - Melbourne, Fitzroy, Victoria, Australia
Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCIS
- Conditions
- Breast CancerOsteoporosis
- First Posted Date
- 2006-05-11
- Last Posted Date
- 2012-11-29
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Registration Number
- NCT00324714
- Locations
- 🇨🇭
Inselspital Bern, Bern, Switzerland
🇨🇭Oncocare Sonnenhof-Klinik Engeriedspital, Bern, Switzerland